Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor

British Journal of Pharmacology

Volumn 147, Issue 5, 2006, Pages 560-568

  Hoi, Pui Man ^a   Hiley, C Robin ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cannabinoid receptors; EDHF; Endothelium; O 1918; Oleamide; Rat mesenteric artery; Rimonabant; SR141716A

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CHARYBDOTOXIN; NITRIC OXIDE SYNTHASE; OLEAMIDE; ORCINOL; RIMONABANT; VANILLOID RECEPTOR;

ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE RELAXATION;

ANIMALS; ARACHIDONIC ACIDS; CAPSAICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; INDOMETHACIN; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; OLEIC ACIDS; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; TRPV CATION CHANNELS; VASODILATOR AGENTS;

EID: 33644827806     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706643     Document Type: Article

References (41)

1. BAKER, D., PRYCE, G., DAVIES, W.L. & HILEY, C.R. (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci., doi:10.1016/j.tips.2005.11.003.
2. + current. J. Biol. Chem., 278, 46188-46194.
3. BISOGNO, T., KATAYAMA, K., MELCK, D., UEDA, N., DE PETROCELLIS, L., YAMAMOTO, S. & DI MARZO, V. (1998). Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells - implications for cell proliferation and differentiation. Eur. J. Biochem., 254, 634-642.
4. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 351, 817-824.
5. BRADSHAW, H.B. & WALKER, J.M. (2005). The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol., 144, 459-465.
6. BUSSE, R., EDWARDS, G., FELETOU, M., FLEMING, I., VANHOUTTE, P.M. & WESTON, A.H. (2002). EDHF: bringing the concepts together. Tr. Pharmacol. Sci., 23, 374-380.
7. CRAVATT, B.F., PROSPERO-GARCIA, O., SIUZDAK, G., GILULA, N.B., HENRIKSEN, S.J., BOGER, D.L. & LERNER, R.A. (1995). Chemical characterization of a family of brain lipids that induce sleep. Science, 268, 1506-1509.
8. DEUTSCH, D.G., GOLIGORSKY, M.S., SCHMID, P.C., KREBSBACH, R.J., SCHMID, H.H., DAS, S.K., DEY, S.K., ARREAZA, G., THORUP, C., STEFANO, G. & MOORE, L.C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest., 100, 1538-1546.
9. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
10. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. & MITCHELL, R.L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443-450.
11. FOWLER, C.J. (2004). Oleamide: a member of the endocannabinoid family? Br. J. Pharmacol., 141, 195-196.
12. FU, J., GAETANI, S., OVEISI, F., LO VERME, J., SERRANO, A., RODRIGUEZ DE FONSECA, F., ROSENGARTH, A., LUECKE, H., DI GIACOMO, B., TARZIA, G. & PIOMELLI, D. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPARα. Nature, 425, 90-93.
13. HILEY, C.R. & FORD, W.R. (2004). Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol. Rev. Camb. Philos. Soc., 79, 187-205.
14. 2+ influx. Br. J. Pharmacol., 139, 585-597.
15. HO, W.S. & HILEY, C.R. (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J. Pharm. Pharmacol., 56, 869-875.
16. HUITRON-RESENDIZ, S., GOMBART, L., CRAVATT, B.F. & HENRIKSEN, S.J. (2001). Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp. Neurol., 172, 235-243.
17. JÁRAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY, N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 14136-14141.
18. KAGOTA, S., YAMAGUCHI, Y., NAKAMURA, K., SUGIURA, T., WAKU, K. & KUNITOMO, M. (2001). 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. Eur. J. Pharmacol., 415, 233-238.
19. LAMBERT, D.M. & DI MARZO, V. (1999). The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr. Med. Chem., 6, 757-773.
20. LAN, R., LIU, Q., FAN, P., LIN, S., FERNANDO, S.R., MCCALLION, D., PERTWEE, R. & MAKRIYANNIS, A. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem., 42, 769-776.
21. 1 receptor knockout mice. Science, 283, 401-404.
22. 1 cannabinoid receptors. Br. J. Pharmacol., 141, 253-262.
23. LICHTMAN, A.H., HAWKINS, E.G., GRIFFIN, G. & CRAVATT, B.F. (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther., 302, 73-79.
24. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., BAYEWICH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
25. MUKHOPADHYAY, S., CHAPNICK, B.M. & HOWLETT, A.C. (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol., 282, H2046-H2054.
26. OFFERTÁLER, L., MO, F.M., BATKAI, S., LIU, J., BEGG, M., RAZDAN, R.K., MARTIN, B.R., BUKOSKI, R.D. & KUNOS, G. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 63, 699-705.
27. O'SULLIVAN, S.E., KENDALL, D.A. & RANDALL, M.D. (2004). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br. J. Pharmacol., 141, 803-812.
28. 9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br. J. Pharmacol., 145, 514-526.
29. PLANE, F., HOLLAND, M., WALDRON, G.J., GARLAND, C.J. & BOYLE, J.P. (1997). Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br. J. Pharmacol., 121, 1509-1511.
30. 1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
31. PRATT, P.F., HILLARD, C.J., EDGEMOND, W.S. & CAMPBELL, W.B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am. J. Physiol., 274, H375-H381.
32. RALEVIC, V., KENDALL, D.A., RANDALL, M.D., ZYGMUNT, P.M., MOVAHED, P. & HOGESTATT, E.D. (2000). Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br. J. Pharmacol., 130, 1483-1488.
33. RANDALL, M.D., ALEXANDER, S.P., BENNETT, T., BOYD, E.A., FRY, J.R., GARDINER, S.M., KEMP, P.A., MCCULLOCH, A.I. & KENDALL, D.A. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun., 229, 114-120.
34. RANDALL, M.D., HARRIS, D., KENDALL, D.A. & RALEVIC, V. (2002). Cardiovascular effects of cannabinoids. Pharmacol. Ther., 95, 191-202.
35. RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G.L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644-650.
36. SHOWALTER, V.M., COMPTON, D.R., MARTIN, B.R. & ABOOD, M.E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989-999.
37. TABERNERO, A., SCHOONJANS, K., JESEL, L., CARPUSCA, I., AUWERX, J. & ANDRIANTSITOHAINA, R. (2002). Activation of the peroxisome proliferator- activated receptor α protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol., 2, 10.
38. WHITE, R. & HILEY, C.R. (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br. J. Pharmacol., 122, 1573-1584.
39. WHITE, R. & HILEY, C.R. (1998). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol., 125, 689-696.
40. WHITE, R., HO, W.S., BOTTRILL, F.E., FORD, W.R. & HILEY, C.R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol., 134, 921-929.
41. ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SORGARD, M., DI MARZO, V., JULIUS, D. & HOGESTATT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457.